Actionable news
0
All posts from Actionable news
Actionable news in TEVA: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DEPOSITARY SHARES,

Teva Pharmaceutical Industries: Teva And University College London Embark On Unique Brain Imaging Study Aimed At Unlocking A NEW APPROACH IN NEURODEGENERATIVE DISEASE

The following excerpt is from the company's SEC filing.

JERUSALEM, November 19, 2015

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and University College London (UCL) announced today the start of a unique study, combining state-of-the-art brain imaging with key biomarkers, aimed at building a better understanding of the role of inflammation in neurodegenerative disease and potentially a new approach in its early diagnosis and treatment.

The Pilot Longitudinal Study in Alzheimers Disease of Central Markers of Microglial Activation (PADMMA) study is a two-year study in 20 patients that will assess, using PET imaging, the prevalence and patter n of activation of a specific type of cell, called microglia, in the central nervous system (CNS) in people with certain symptoms of neurodegenerative disease. It is key demonstration of Tevas commitment towards dementia research made following the UK Governments Dementia Summit, spearheaded by UK Prime Minister David Cameron.

The role of inflammation is key in the field of neurodegeneration. It is implicated in the neuronal dysfunction that is the result of some of the most devastating neurodegenerative diseases. Microglia play a central role in neuro-inflammation, and defining reliable biomarkers of microglial activation, and their changes over time, will provide us with crucial information for developing treatment trials with neuro-inflammation as a novel therapeutic target.

This is a very exciting new direction. The insights into the role of microglial activation provided by the study will facilitate the development of reliable central and peripheral clinical markers of inflammation early on in Alzheimers disease, potentially providing tools to assess the impact of drugs on a new therapeutic target, said Dr Cath Mummery, Consultant Neurologist and Clinical Lead at the DRCs Cognitive Disorders Clinic.

The focus on microglial activation heralds a new therapeutic area of interest for most neurodegenerative diseases, potentially with very high impact on disease modification therapies, said Doctor Michael Hayden, Tevas President of R&D and Chief Scientific Officer. The PADMMA study has clear translational value. A greater understanding of the role of brain inflammation in early disease may lead to development of better biomarkers that could better inform therapeutic studies and potentially open the door to new therapeutic options.

The study will be performed at the University College London (UCL) Dementia Research Centre (DRC) for which Dr Mummery is Clinical Trials lead, and the Leonard Wolfson Experimental Neurology Centre (LWENC) Clinical Research Facility (CRF), headed by Dr Vincenzo Libri, who is also Co-Investigator of the PADMMA study. Imaging will be undertaken by Imanova, at the Centre for Imaging Sciences, Imperial College London.

This unique study is the result of an extensive collaborative effort supported by the

UK Israel Tech Hub

at the British Embassy in Israel helping Teva, UCL and Imanova, come together in an effort to change the paradigm in neurodegenerative disease.

David Quarrey, UK Ambassador to Israel, said: We welcome this project, part of Tevas multi-million commitment to deepen its research in the UK. Over the years, Teva has proved a great partner to the UKs world-class medical research institutions. The UK Israel Tech Hub remains committed to creating more bilateral collaborations in innovation, for the benefit of patients in both countries and around the world.

About the PADMMA Study

The Pilot Longitudinal Study in Alzheimers Disease of Central Markers of Microglial Activation (PADMMA) study is a two-year study in 20 patients that will assess the prevalence and pattern of CNS microglial activation in individuals with prodromal AD with Mild Cognitive Impairment (MCI) or mild AD through the use of PET imaging and comparison with CSF and peripheral markers of inflammation..

The total study duration will be 2 years, with 1 year for the recruitment period. The study duration for each participant is 12 months. It will be run between the DRC and the LWENC CRF at the UCL Institute of Neurology (IoN) and the UCLH National Hospital for Neurology and Neurosurgery (NHNN). Dr Cath Mummery is Consultant Neurologist and Clinical Lead at the DRCs Cognitive Disorders Clinic University College London Hospital (UCLH), and is supported by the NIHR Queen Square Biomedical Research Unit (BRU) and NIHR UCLH BRC...


More